Red light therapy (RLT) supports respiratory healing by delivering red and near-infrared wavelengths that penetrate the chest wall to reach lung tissue, where they stimulate mitochondrial energy production, reduce airway inflammation, and modulate immune responses.
For pneumonia recovery, a 2021 clinical pilot study demonstrated that PBM-treated patients had zero ICU admissions compared to 60% in controls, with average hospital stay reduced from 12 to 7 days. For COPD, a 2018 trial found PBM significantly increased exercise steps and decreased breathlessness perception. For allergic rhinitis, a 2025 randomized trial showed significant improvements in nasal airflow and symptom control after eight sessions.
For optimal results, use RLT 3-5 times weekly for chronic conditions or daily during acute respiratory infections. Choose FDA-cleared devices combining 630-660 nm red and 810-940 nm near-infrared wavelengths. Always wear proper eye protection and avoid direct irradiation over known cancerous lung masses without medical approval.
This article details 14 respiratory conditions RLT helps, including asthma, bronchitis, congestion, chronic sinusitis, COPD, cough, emphysema, lung inflammation, pneumonia recovery, pulmonary fibrosis, upper respiratory infection, allergic rhinitis, dyspnea, and rhinosinusitis. It also outlines things you must know before trying RLT, how RLT works for respiratory healing, how to choose the right device, optimal usage frequency, precautions, at-home use, expected timelines for improvement, and other conditions RLT can treat.
The goal of this article is to educate readers with respiratory concerns about how RLT can improve their lung health and recovery at home and support ongoing treatments.
1. Asthma
Asthma is a chronic inflammatory disease of the airways affecting an estimated 300 million people worldwide. It manifests as recurrent wheezing, breathlessness, and airway hyperresponsiveness.
Photobiomodulation (PBM) reduces lung inflammation in asthma by modulating mast cell degranulation and increasing anti-inflammatory interleukin-10 (IL-10) levels while decreasing Th2 cytokines like IL-4, IL-5, and IL-13. It also increases regulatory T cells (Tregs) in lung tissue.
Device Type to Use
Handheld LED clusters or flexible pads with 630-850 nm wavelengths are suitable for at-home respiratory application, positioned over the sternum and upper back for 10-20 minutes per session. For clinical use, photohemotherapy devices that treat blood extracorporeally have shown immunological benefits.
Recommended RLT Parameters
Preclinical studies demonstrate efficacy with 660 nm red light at 33.3 mW/cm² irradiance, delivering 5.35 J/cm² energy density over 150 seconds per application point. For chronic asthma models, 660 nm at 100 mW for 50 seconds per point (5 J total) applied to three locations was effective. A 610 nm wavelength at 1.7 mW/cm² applied 20 minutes daily for 19 days reduced airway inflammation. Follow a treatment frequency of 3-7 times weekly for 4-12 weeks.
Before & After Results
In a 480-patient clinical study, photohemotherapy significantly increased CD3+ lymphocytes (from 32.34% to 60.73%) and CD4+ helper cells (from 17.94% to 38.55%), while decreasing IgE levels (from 68.3% to 60.2%) and circulating immune complexes (from 54.5% to 40.3%). IL-4 levels dropped nearly to normal (68.55 pg/mL) while IL-10 increased to 3.91 pg/mL. Animal studies show reduced airway hyperresponsiveness, decreased eosinophil infiltration, and diminished goblet cell hyperplasia following PBM treatment.
2. Bronchitis
Bronchitis is an inflammatory condition of the bronchial tubes. It is characterized by cough, mucus production, and airway inflammation, often following viral infection.
Photobiomodulation reduces bronchitis-related inflammation by modulating pro-inflammatory cytokines like TNF-α, IL-6, and IL-8 while decreasing neutrophil migration to lung tissue and reducing airway edema. It also enhances ATP production in lung cells through cytochrome c oxidase activation.
Device Type to Use
Handheld LED panels or flexible pads with 630-850 nm wavelengths are suitable for at-home application, positioned over the sternum and upper back for 10-20 minutes per session. For optimal coverage, devices combining red and near-infrared light in a single applicator are recommended.
Recommended RLT Parameters
For deep airway inflammation, use near-infrared wavelengths of 800-940 nm to penetrate to bronchial tissues. Deliver energy density of 40-100 J/cm² at a power density of 1.5-3 W/cm², with irradiation times of 40-100 seconds per point. For systemic immune modulation, wavelengths of 660-808 nm with 50-150 J/cm² energy density applied 3-5 times weekly for 2-4 weeks are effective. Target the upper chest and upper back regions for comprehensive bronchial coverage.
Before & After Results
A clinical trial protocol for bronchiolitis (viral bronchitis in infants) demonstrates that transcutaneous photobiomodulation reaches lung tissue and produces positive responses by reducing airway edema, decreasing neutrophil migration, and downregulating TNF-α, IL-6, and IL-10 levels. Research shows PBM reduces inflammatory cell infiltration and supports faster resolution of airway inflammation compared to conventional treatment alone. These anti-inflammatory effects translate to reduced cough severity and improved breathing comfort.
3. Congestion
Nasal congestion is a common respiratory symptom caused by inflammation and swelling of nasal tissues, often associated with allergic rhinitis, sinusitis, or viral infections.
Photobiomodulation works on congestion by inhibiting pro-inflammatory cytokines and stimulating mitochondrial ATP production in nasal epithelial cells. It also promotes vasodilation through nitric oxide release, improving blood circulation to clear inflammatory exudates.
Device Type to Use
Intranasal LED probes or handheld devices with nasal attachments are ideal for at-home congestion treatment, delivering light directly into the nasal cavity. For broader coverage, flexible pads can be positioned over the sinuses.
Recommended RLT Parameters
Use red light at 660 nm combined with near-infrared at 850-940 nm for comprehensive treatment. A clinical trial delivered 40 mW per nostril for 15 minutes, providing 36 J per nostril per session. Another study used 660 nm and 940 nm, 3 minutes per cycle, 3 times daily for 2 weeks. For chronic rhinosinusitis, 904 nm at 2.5 J per point, 10-minute sessions, 12 sessions total showed efficacy.
Before & After Results
A 2-week LED study showed total allergic rhinitis symptom scores decreased by 67% with 17% reduction in serum IgE levels. A single 15-minute treatment significantly improved nasal congestion, runny nose, and sneezing within 30 minutes. For chronic rhinosinusitis, 12 PBM sessions significantly improved headache, fatigue, and sinus opacification versus sham.
4. Chronic Sinusitis
Chronic sinusitis is a persistent inflammatory condition of the paranasal sinuses lasting over 12 weeks, affecting millions worldwide with symptoms including facial pressure, congestion, and fatigue.
PBM helps chronic sinus inflammation by promoting mitochondrial activity in sinus tissues and shifting macrophages from pro-inflammatory M1 to anti-inflammatory M2 phenotypes. This modulates key signaling pathways, including NF-κB, and reduces pro-inflammatory cytokines like TNF-α and IL-1β.
Device Type to Use
Class IV therapy lasers (810-1064 nm) with higher irradiance are preferred for trans-osseous penetration through the facial skeleton. For at-home use, intranasal LED probes with 660 nm red light or flexible panels placed over the cheeks and forehead are suitable alternatives.
Recommended RLT Parameters
A systematic review and meta-analysis of 6 studies (162 patients) demonstrated efficacy with near-infrared wavelengths of 810-940 nm. For trans-facial application, deliver 8-10 J/cm² energy density at 8-12 W power, 20-50 Hz pulsed mode, 2-3 times weekly for 4 weeks, with 3,000 J total energy per session for maxillary sinuses. Intranasal devices typically use 660 nm red light for 10-15 minutes per session.
Before & After Results
A 2025 meta-analysis showed significant improvement in subjective symptom scores at 2 weeks and sustained benefit at 2-6 months. A clinical case study documented a reduction in mucosal thickening from 5 mm to 1.5 mm on CT scan after 6 weeks, with Visual Analog Scale for facial pain dropping from 8/10 to 1/10 at 10-week follow-up. Another study reported SNOT-20 score improvement of 0.8-0.9 points with therapeutic effect sustained for minimum 2 months.
5. COPD (Chronic Obstructive Pulmonary Disease)
COPD (Chronic Obstructive Pulmonary Disease) is a progressive inflammatory lung disease affecting over 300 million people globally. It is characterized by persistent airflow limitation, chronic airway inflammation, and debilitating breathlessness that ranks as the third leading cause of death worldwide.
Photobiomodulation helps COPD-related lung inflammation by inhibiting pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-17) while increasing anti-inflammatory IL-10, decreasing neutrophil recruitment, and reducing alveolar enlargement. It enhances mitochondrial ATP production via cytochrome c oxidase activation, improving respiratory and peripheral muscle metabolism and promoting angiogenesis in lung tissues.
Device Type to Use
Handheld LED clusters or flexible pads combining red and near-infrared diodes are suitable for at-home application over the sternum, upper back, and respiratory muscles. Clinical trials have successfully used clusters containing 35 red (630 nm) and 34 near-infrared (830 nm) LEDs applied to the main respiratory muscles. For lower limb applications to improve exercise capacity, clusters with 4 × 905 nm super-pulsed laser diodes, 4 × 875 nm infrared LEDs, and 4 × 640 nm red LEDs applied to 17 sites per lower limb are effective.
Recommended RLT Parameters
For lung inflammation reduction, use wavelengths of 660-830 nm delivering 3-10 J/cm² energy density, with irradiation times of 30-60 seconds per point applied to the trachea and both lung lobes. For respiratory muscle application, use a cluster with 630 nm red (10 mW) and 830 nm near-infrared (10 mW) LEDs applied to the main respiratory muscles. For lower limb application to improve exercise tolerance, apply 30 J per site across 17 sites on each lower limb using a cluster combining 905 nm laser, 875 nm infrared LED, and 640 nm red LED. Follow a treatment frequency of 2-3 sessions per week for 4 weeks, with sessions lasting 10-20 minutes per targeted area.
Before & After Results
A 2023 narrative review of 12 studies concluded that PBM reduces lung inflammation through decreased inflammatory cytokines and chemokines at multiple levels while increasing anti-inflammatory cytokines, with animal studies showing decreased leukocytes in bronchoalveolar lavage fluid, reduced collagen deposition, and improved lung mechanics. A randomized crossover trial of 12 COPD patients demonstrated a significant increase in 6-minute walk test distance after PBM intervention. Another clinical trial of 21 COPD patients found that PBMT applied before exercise significantly increased the number of steps during cardiopulmonary testing, decreased perception of breathlessness, and reduced lower limb fatigue. A human study also demonstrated immunomodulatory effects with decreased pro-inflammatory markers.
6. Cough
Cough is a common respiratory reflex often driven by underlying airway inflammation. It is frequently associated with conditions like asthma, bronchitis, and viral infections.
PBM reduces cough by decreasing lung inflammation, inhibiting mast cell degranulation, and increasing anti-inflammatory interleukin-10 (IL-10) levels. It also suppresses pro-inflammatory cytokines such as IL-4, IL-5, and IL-13 by inhibiting the NF-κB signaling pathway, addressing the root cause of airway irritation.
Device Type to Use
Handheld LED clusters or flexible pads with red and near-infrared wavelengths are suitable for at-home use, positioned over the sternum, trachea, and upper back for 10-20 minutes per session. Intranasal probes may also be used for upper airway involvement.
Recommended RLT Parameters
Use red light at 660 nm and near-infrared at 830-850 nm. Deliver energy density of 3-8 J/cm² at the skin surface over the trachea and peristomal region. For deeper penetration, near-infrared at 810-830 nm with 4-8 J per point is recommended. Apply treatment 2-3 times weekly for 2-4 weeks, with sessions lasting 10-20 minutes. A clinical protocol using 660 nm at 5.35 J/cm² over 150 seconds demonstrated efficacy.
Before & After Results
A 2025 clinical study of 80 pediatric cough patients found that red light irradiation combined with topical treatment achieved a 97.50% total effective rate, significantly higher than the control group's 85.00%. C-reactive protein, interleukin-6, and serum amyloid A levels were significantly reduced after 3 and 7 days of treatment. A separate study of 160 children with post-infection cough reported that far infrared spectrum treatment significantly improved cough and lung rale symptom scores compared to conventional therapy alone, with no adverse reactions observed. Animal studies show PBM reduces cell migration and mast cell degranulation while increasing IL-10 levels in lung tissue.
7. Emphysema
Emphysema is a progressive lung condition characterized by irreversible alveolar destruction and airflow obstruction, forming part of chronic obstructive pulmonary disease (COPD).
Photobiomodulation supports emphysema-related lung inflammation treatment by inhibiting NF-κB inflammatory signaling pathways and decreasing pro-inflammatory cytokines (IL-4, IL-5, IL-13) while promoting anti-inflammatory IL-10 production. Near-infrared light penetrates deep into lung tissue (up to 15 cm) to modulate immune responses.
Device Type to Use
Handheld LED clusters or flexible pads with high-power near-infrared diodes are suitable for at-home emphysema treatment, positioned over the sternum, upper back, and lateral chest for comprehensive lung coverage. Devices utilizing a 980 nm wavelength with deep tissue penetration are preferred.
Recommended RLT Parameters
Use near-infrared wavelengths of 980 nm for maximum deep tissue penetration to reach alveolar structures. Deliver energy density of 3-8 J/cm² per point over the chest and back regions. For respiratory muscle application, use 808-830 nm delivering 4-8 J per point across multiple points. Apply treatment 2-3 times weekly for 4-8 weeks, with sessions lasting 10-20 minutes per targeted area.
Before & After Results
Preclinical studies demonstrate that photobiomodulation reduces inflammatory cell infiltration and mast cell degranulation in lung tissue while increasing IL-10 levels, leading to decreased alveolar inflammation. Research confirms downregulation of Th2 cytokines (IL-4, IL-5, IL-13) that drive airway remodeling and tissue damage. It noted that animal models consistently show reduced pulmonary inflammation following PBM treatment, though clinical trials in humans remain limited and require longer intervention periods.
8. Lungs (Respiratory Inflammation/Function)
Respiratory inflammation is a key driver of lung dysfunction in conditions like asthma, COPD, and post-viral syndromes, affecting millions with impaired breathing and reduced quality of life.
Photobiomodulation reduces lung inflammation by stimulating mitochondrial cytochrome c oxidase, increasing ATP production while displacing inhibitory nitric oxide. This suppresses NF-κB signaling, downregulates pro-inflammatory cytokines (TNF-α, IL-6, IL-8), and reduces neutrophil infiltration.
Device Type to Use
Flexible LED panels or vests with arrays of red and near-infrared diodes are most effective for at-home lung treatment, allowing comprehensive coverage of the thoracoabdominal region. Clinical studies have successfully used vests with 300 LEDs positioned over the anterior chest and abdomen for 15-minute sessions.
Recommended RLT Parameters
Use near-infrared wavelengths of 940 nm for deep lung penetration, delivering 6 W total power over 15 minutes per session. For red light protocols, 660 nm at 100 mW with 1-3 J energy per point, applied for 10-30 seconds per location, is effective. Apply treatment daily for 5-7 days or 2-3 times weekly for 4 weeks, with 10-20 minute sessions.
Before & After Results
A 2023 randomized controlled trial of 30 COVID-19 patients receiving five PBM sessions showed significant improvements in oxygen saturation, with reduced CRP, IL-6, and ferritin levels compared to controls. A 2025 COPD animal study demonstrated that 660 nm PBM at 1-3 J doses significantly reduced inflammatory cell infiltration, with 1 J showing the most pronounced anti-inflammatory effects. A 2022 study using 940 nm LED vests in COVID-19 patients reported improved tidal volume, inspiratory pressure, and reduced hospital discharge time. Post-COVID pulmonary fibrosis patients receiving 940 nm PBM twice weekly for 6 weeks showed significant improvements in MIP, MEP, FEV1, and the 6-minute walk test.
9. Pneumonia (Supportive Recovery)
Pneumonia is an acute respiratory infection causing lung inflammation and fluid accumulation, responsible for an estimated 2.5 million deaths annually worldwide, with supportive recovery being critical for reducing mortality and long-term complications.
Photobiomodulation (PBM) reduces pneumonia-related lung inflammation by inhibiting the NF-κB inflammatory signaling pathway, decreasing pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, and IL-8, while promoting anti-inflammatory mediators like IL-10. Near-infrared light penetrates up to 15 cm into lung tissue, modulating immune responses and reducing neutrophil infiltration and oxidative stress.
Device Type to Use
Flexible LED vests with arrays of 300 near-infrared diodes or MLS laser systems with synchronized 808 nm and 905 nm diodes are most effective for pneumonia recovery, allowing comprehensive coverage of the thoracic and abdominal regions. For at-home supportive use, high-power flexible panels or vests combining red and near-infrared wavelengths that can be positioned over the anterior chest and upper back are recommended. Clinical protocols typically use a laser scanner placed 20 cm above the patient across the lung fields while in the prone position.
Recommended RLT Parameters
Use near-infrared wavelengths of 808-940 nm for deep lung penetration, with 905 nm and 808 nm synchronized lasers showing clinical efficacy. Deliver 7.2 J/cm² over the skin surface, which penetrates to deliver approximately 0.01 J/cm² to lung tissue. For LED vests, deliver 6 W total power for 15 minutes daily, providing 5,400 J total energy per session. Apply treatment once daily for 4-7 consecutive days, with sessions lasting 15-28 minutes per treatment. For red light protocols, 650 nm at 80 mW for 10 minutes, repeated every 6 hours (three times within 24 hours), demonstrated efficacy in preclinical models.
Before & After Results
A 2021 randomized clinical pilot study of 10 COVID-19 pneumonia patients showed PBM-treated patients had a mean hospital stay of 7 days versus 12 days in controls, with 0% ICU admission compared to 60% in controls requiring mechanical ventilation. Oxygen saturation (SpO2) increased from 93-94% to 98-100% within 5-10 minutes of treatment, with RALE Chest X-ray score improving from 8 to 5.2. A 2022 study of 21 community-acquired pneumonia patients demonstrated significant recovery differences in the LED group for erythrocytes, hemoglobin, leukocytes, and lymphocytes, with lymphocyte count reduction of 60% versus 16% in controls and erythrocyte increase of 86% versus 35%. Preclinical models of septic acute lung injury showed PBM prolonged survival, reduced lung edema, improved histopathology, and lowered systemic TNF-α, IL-6, IL-1β, and MCP-1 while increasing anti-inflammatory IL-4, IL-10, and IL-13.
10. Pulmonary Fibrosis
Pulmonary fibrosis is a devastating interstitial lung disease characterized by progressive scarring of lung tissue, excessive collagen deposition, and irreversible functional decline, with limited treatment options available worldwide.
Photobiomodulation works on pulmonary fibrosis by decreasing inflammatory cell infiltration into alveolar spaces, lowering pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), and suppressing collagen production while reducing interstitial thickening and pulmonary elastance. Near-infrared light penetrates deep into lung tissue to modulate immune responses and restore antioxidant capacity.
Device Type to Use
Flexible LED vests with arrays of 300 near-infrared LEDs (940 nm) are the most effective device type for pulmonary fibrosis treatment, providing comprehensive coverage of the thoracoabdominal region. For targeted application, Class IV lasers (10+ watts) applied over the chest and back for 5 minutes per site have been used in anecdotal protocols. Multi-wavelength devices combining red and near-infrared with static magnetic fields have also shown efficacy
Recommended RLT Parameters
Preclinical studies demonstrate efficacy with 660 ± 20 nm red light at 100 mW power, delivering 5 J/cm² radiant exposure with 33.3 mW/cm² irradiance over 150 seconds per point (15 J total energy), applied to the thorax once daily for 8 days. For photodynamic therapy applications, 650 nm irradiation with 25 J/cm² delivered weekly via thoracic irradiation demonstrated anti-fibrotic effects. For LED vests, use a 940 nm wavelength with 6 W total optical power for 15 minutes per session. For multi-wavelength PBMT-sMF, deliver 31.50 J per irradiated site with 60 seconds treatment time per site across 8 sites (6 on thorax/abdomen, 2 on neck), applied once daily for 45 days. Clinical protocols suggest 2-3 sessions weekly for 4-8 weeks for maintenance, with a total energy of 5,400 Joules per session for Class IV laser applications.
Before & After Results
Preclinical studies in bleomycin-induced pulmonary fibrosis models show that PBM significantly reduces inflammatory cells in the alveolar space, decreases collagen production, reduces interstitial thickening, and improves static and dynamic pulmonary elastance. Photodynamic therapy with novel photosensitizers (650 nm, 25 J/cm²) significantly inhibited fibroblast proliferation, improved survival rates, reduced collagen deposition, and suppressed pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) while restoring antioxidant capacity (SOD, GSH). A 2024 prospective study of 30 post-COVID-19 pulmonary fibrosis patients using 940 nm LED vests twice weekly for 6 weeks demonstrated statistically significant improvements in MIP (maximal inspiratory pressure), MEP (maximal expiratory pressure), FEV1 (forced expiratory volume), and 6-minute walk test distance. A 2021 case report documented that a patient receiving PBMT-sMF once daily for 45 days was able to leave oxygen support, increased SpO2 from 89% to 96-98%, improved RALE (Radiographic Assessment of Lung Edema) severity score from 8 to 0 (indicating total lung recovery), and maintained normal respiratory mechanics parameters at 4-month follow-up.
11. Upper Respiratory Infection
Upper respiratory infection (URI) is a common viral illness affecting the nose, throat, and sinuses.
Photobiomodulation works on URI symptoms by delivering light to the oropharynx and nasal tissues, where it stimulates host immune factors and reduces viral replication through modulation of inflammatory pathways. Intranasal light application has been shown to reduce cytokine levels and accelerate recovery of respiratory symptoms.
Device Type to Use
Intranasal LED probes combined with chest pads are the most effective device type for at-home URI treatment, allowing simultaneous delivery of light to both upper airways and lung fields. Devices combining 635 nm intranasal applicators with 810 nm chest LEDs have demonstrated clinical efficacy in large-scale trials.
Recommended RLT Parameters
Use 635 nm red light intranasally combined with 810 nm near-infrared on the chest for comprehensive airway treatment. Deliver 20-minute sessions twice daily for 5 days, followed by once daily for 30 days. For superficial peristomal application, use 630-660 nm red or 800-830 nm near-infrared delivering 3-6 J/cm², applied 2-3 times weekly for 2-4 weeks. For deeper pretracheal tissues, 810-830 nm at 4-8 J/cm² is recommended.
Before & After Results
A 2024 randomized controlled trial of 199 COVID-19 patients demonstrated that patients receiving PBMT within 7 days of symptom onset recovered significantly faster, with median recovery time of 18 days versus 21 days for controls. No deaths or severe adverse events occurred in the treatment group, whereas the control group experienced 1 death and 3 severe events requiring hospitalization. A 2024 study of 70 children with rhinitis and sinusitis confirmed that pulsed red light combined with thermotherapy and magnetic field produced anti-inflammatory and decongestant effects, reducing overall treatment time.
12. Allergic Rhinitis
Allergic rhinitis is a common inflammatory condition of the nasal mucosa affecting an estimated 400 million people worldwide, triggered by allergen exposure and characterized by sneezing, congestion, and nasal itching.
Photobiomodulation heals allergic rhinitis symptoms by shifting macrophages from pro-inflammatory M1 to anti-inflammatory M2 phenotypes, decreasing Th2 cytokines while promoting tissue homeostasis in the nasal mucosa. Red and near-infrared light is absorbed by mitochondrial cytochrome c oxidase, increasing ATP production and modulating NF-κB signaling to reduce inflammation.
Device Type to Use
Intranasal LED or laser probes are the most effective device type for at-home treatment of allergic rhinitis, delivering light directly to the nasal mucosa. Handheld devices with dual nasal probes allow simultaneous treatment of both nostrils, while external probes can be positioned over the nasal bridge for supplemental infrared application.
Recommended RLT Parameters
Use red light at 650-660 nm combined with near-infrared for comprehensive treatment. A 2025 randomized controlled trial delivered 6 J of red and infrared light intranasally plus 1 J of infrared light externally per session. A clinical protocol using 660 nm at 40 mW per nostril delivered 36 J per nostril over 15 minutes. The recommended safe energy dose ranges from 1 to 10 Joules per treatment. Apply treatment twice weekly for 4 weeks (8 sessions total), with sessions lasting 15-20 minutes.
Before & After Results
A 2025 placebo-controlled randomized clinical trial of 62 patients demonstrated significant improvements in peak nasal inspiratory flow, Nasal Obstruction Symptom Evaluation scores, and Rhinitis Control Assessment Test scores (following eight sessions over four weeks. A clinical trial protocol using 660 nm at 40 mW per nostril for 15 minutes showed measurable improvements in nasal resistance and cross-sectional area within 30 minutes of a single treatment.
13. Dyspnea (Shortness of Breath)
Dyspnea (shortness of breath) is a distressing symptom affecting millions with chronic respiratory diseases like COPD. It is characterized by the perception of breathing discomfort that significantly limits daily activities and quality of life.
Photobiomodulation treats dyspnea by improving mitochondrial energy production and enhancing surfactant production in lung epithelial cells, which facilitates alveolar expansion and oxygen exchange. It also decreases the sensation of breathlessness by reducing respiratory muscle fatigue and lowering the perception of exertion during physical activity.
Device Type to Use
Flexible LED vests or handheld panels with near-infrared diodes are the most effective device types for at-home dyspnea treatment, allowing comprehensive coverage of the thoracoabdominal region. For targeted respiratory muscle application, clusters combining super-pulsed laser diodes with red and infrared LEDs applied to multiple sites on the lower limbs and thorax have demonstrated clinical efficacy.
Recommended RLT Parameters
Use red light at 640 nm combined with near-infrared at 875 nm and 905 nm for comprehensive treatment. A clinical trial protocol delivered 30 J per site across 17 sites on each lower limb using a cluster of 4 × 905 nm super-pulsed laser diodes, 4 × 875 nm infrared LEDs, and 4 × 640 nm red LEDs. For lung tissue application, 660 nm and 830 nm wavelengths delivered at 3-15 J/cm² energy density significantly increased surfactant protein production. Apply treatment 2-3 times weekly for 4-8 weeks, with sessions lasting 15-20 minutes per targeted area.
Before & After Results
A 2018 randomized crossover trial of 21 COPD patients demonstrated that PBMT applied before exercise significantly increased the number of steps during the 6-minute stepper test and decreased perception of breathlessness and lower limb fatigue compared to placebo. A 2024 prospective study of 30 post-COVID pulmonary fibrosis patients using 940 nm LED vests twice weekly for 6 weeks showed statistically significant improvements in maximal inspiratory pressure, maximal expiratory pressure, FEV1, and 6-minute walk test distance. A 50-patient COVID-19 case study reported that acute dyspnea, lung congestion, and hypoxia were eliminated in 41/50 patients within 4 days of commencing PBM treatments, with SpO₂ concentrations improving as much as 9 points (average 2.5 points) across the study population.
14. Rhinosinusitis
Rhinosinusitis is an inflammatory condition affecting the nasal passages and paranasal sinuses. It manifests as mucosal inflammation, congestion, and facial pressure, affecting millions with both acute and chronic forms.
Photobiomodulation treats rhinosinusitis inflammation by shifting macrophages from pro-inflammatory M1 to anti-inflammatory M2 phenotypes, promoting mitochondrial activity and increasing ATP production in sinus tissues. It also decreases pro-inflammatory cytokines, including IL-1β and TNF-α, while enhancing tissue repair and restoring mucosal homeostasis.
Device Type to Use
Intranasal LED or laser probes are most effective for at-home rhinosinusitis treatment, delivering light directly to the nasal cavity and sinus ostia. For comprehensive coverage, devices combining intranasal probes with external facial panels can treat both anterior and posterior sinuses. Class IV therapy lasers with 810-1064 nm wavelengths provide deeper trans-osseous penetration through facial bones to reach the maxillary and frontal sinuses.
Recommended RLT Parameters
A clinical trial protocol using 660 ± 10 nm red laser delivered 40 mW per nostril for 15 minutes, providing 36 J total energy per nostril per session. For deeper sinus penetration, Class IV laser protocols use 810-1064 nm wavelengths with 8-10 J/cm² energy density at 8-12 W power, pulsed mode at 20-50 Hz, applied 2-3 times weekly for 4 weeks. For LED devices, 630-660 nm red light with 633 nm showing clinical efficacy is recommended. Go for a treatment frequency of 2-3 sessions weekly for 4 weeks, with repeat courses recommended every 9-12 months for isolated rhinosinusitis.
Before & After Results
A clinical case study of a 42-year-old chronic rhinosinusitis patient with 5 mm mucosal thickening on CT scan showed complete resolution after 6 weeks of Class IV laser treatment (810-1064 nm, twice weekly for 4 weeks), with mucosal thickening reduced from 5 mm to 1.5 mm, facial pain Visual Analog Scale dropping from 8/10 to 1/10 at 10-week follow-up, and the patient canceling scheduled sinus surgery. A Russian clinical study using 633 nm red laser in complex rehabilitation for rhinosinusitis with nasal polyposis demonstrated positive clinical outcomes with prolonged remission periods. Research confirms that PBM reduces inflammatory markers, enhances tissue repair, and promotes mucosal healing through M2 macrophage polarization.
What should You know about using Red Light Therapy for Respiratory Conditions?
Before using red light therapy for respiratory healing, it is essential to understand how light energy interacts with lung tissue and airway structures, what device specifications are necessary to achieve meaningful penetration to the bronchial passages, and treatment frequency and duration. You must also know what precautions to take to integrate it safely alongside conventional respiratory treatments, whether you can take it at home, how long you need to see results, and what other conditions RLT can treat.
How does Red Light Therapy Work for Respiratory Conditions?
Red light therapy works for respiratory conditions by delivering specific wavelengths of red (630-660 nm) and near-infrared (810-940 nm) light that penetrate the chest wall and reach the lungs, bronchial tissues, and airway mucosa.
Within these cells, photons are absorbed by cytochrome c oxidase in the mitochondria, triggering a cascade that increases adenosine triphosphate (ATP) production while reducing oxidative stress and inhibiting the NF-κB inflammatory pathway.
This dual action downregulates pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β, while promoting anti-inflammatory mediators such as IL-10.
Additionally, photobiomodulation improves local circulation, reduces mucus hypersecretion, enhances surfactant production in alveoli, and supports the regeneration of damaged epithelial cells lining the airways.
How to Choose the Right Red Light Device for Respiratory Conditions?
To choose the right red light device for respiratory conditions, prioritize systems with sufficient near-infrared power to penetrate the chest wall and reach deep lung structures, along with regulatory clearance for safety and efficacy. Below is a detailed guide:
- Prioritize FDA Clearance or CE Marking: Select devices with regulatory certification to ensure they meet safety standards and deliver consistent, therapeutic output.
- Match Wavelength to Target Depth: Use red light (630-660 nm) for superficial airway tissues and near-infrared (810-940 nm) for deeper penetration required to reach the lungs, bronchi, and alveolar structures.
- Select Appropriate Applicator Type: For comprehensive lung coverage, choose flexible LED vests or large panels that can cover the anterior chest, sternum, and upper back simultaneously. For targeted airway treatment, handheld clusters or intranasal probes are suitable.
- Ensure Sufficient Power Output: Verify the device delivers therapeutic irradiance (measured in mW/cm²) capable of penetrating tissue depth to reach the target respiratory structures, as supported by clinical pulmonary studies.
- Look for Large Treatment Areas: Because the lungs are bilateral and extend across the thorax, a device with a wide panel or vest design ensures both lung fields receive adequate exposure in a single session.
- Consider Multi-Wavelength Capability: Devices combining both red and near-infrared wavelengths offer comprehensive treatment for both superficial airway inflammation and deep lung pathology.
How Frequently should You use Red Light Therapy for Respiratory Conditions?
For respiratory conditions, treatment frequency ranges from 5 days to 12 months, depending on whether the condition is acute or chronic.
For acute respiratory infections like bronchitis or pneumonia, use red light therapy once or twice daily for 5-7 consecutive days to support rapid resolution of inflammation.
For chronic respiratory conditions such as COPD, asthma, or pulmonary fibrosis, apply treatment 3-5 times weekly for 4-8 weeks initially, then reduce to 2-3 sessions weekly for maintenance.
Allergic rhinitis and sinusitis respond well to 2-3 sessions weekly for 4 weeks, with repeat courses every 9-12 months as needed.
What Precautions Should You Take Before Red Light Therapy?
Before starting red light therapy for respiratory conditions, you must take the following precautions to ensure safe and effective treatment:
- Consult a pulmonologist or healthcare provider for proper diagnosis, especially for conditions like COPD, asthma, or pulmonary fibrosis, as light therapy should complement, not replace, prescribed medications.
- Always wear wavelength-specific protective goggles to prevent retinal damage, even when treating the chest or back, as bright light exposure can affect circadian rhythms and sleep patterns.
- Use only FDA-cleared or CE-marked devices to ensure wavelength accuracy, output stability, and safety compliance.
- Avoid direct irradiation over known cancerous lung masses without oncology approval, as photobiomodulation may stimulate cellular activity in undiagnosed malignancies.
- Exercise caution with photosensitising medications. If you are taking antibiotics like tetracyclines, retinoids, or St. John's Wort, consult your doctor, as these can increase photosensitivity and tissue reaction risk.
- Be mindful of treatment timing. Avoid treating the chest too close to bedtime if you are sensitive to stimulation, as near-infrared light can be mildly activating for some individuals.
Can You take Red Light Therapy at Home?
Yes, you can safely use red light therapy at home to support respiratory healing, provided you select a device with sufficient power to penetrate the chest wall and adhere to established safety protocols. Here is what you need for safe at-home use:
- An FDA-cleared or CE-marked device with adequate power output, which can be a flexible LED vest or a large panel capable of covering both lung fields simultaneously.
- Wavelength-specific protective goggles to protect your eyes from direct or reflected light exposure during sessions.
- A confirmed diagnosis from a healthcare provider ensures that stimulating respiratory tissues is appropriate for your specific condition.
- Clear manufacturer guidelines regarding treatment distance (if using panels), session duration, and positioning for optimal lung coverage.
- A device with proper heat management to prevent skin discomfort, particularly for longer treatment sessions.
How Long does it take to See Improvements?
Improvements from red light therapy for respiratory conditions typically appear within 3 days to 12 weeks, depending on the acuity and severity of the condition.
For acute conditions like bronchitis, pneumonia, or upper respiratory infections, symptom relief, such as reduced coughing, improved breathing, and decreased congestion, can begin within 3-7 days of consistent daily sessions. For chronic conditions like COPD, asthma, and pulmonary fibrosis, initial improvements in breathlessness, exercise tolerance, and oxygen saturation often emerge within 2-4 weeks, with more substantial functional gains and biomarker changes evident at 6-12 weeks. Allergic rhinitis symptom reduction (sneezing, nasal congestion) is frequently reported after 2 weeks of twice-weekly treatment, with sustained improvement following a full 4-week course.
What Other Conditions Can Red Light Therapy Treat?
Beyond respiratory healing, red light therapy treats a broad range of other health conditions, including the following:
- Pain management for osteoarthritis, arthritis, tendinopathy, neck pain, lower back pain, fibromyalgia, and plantar fasciitis
- Muscle recovery and sports performance enhancement
- Skin rejuvenation, acne treatment, wound healing, and scar reduction
- Hair restoration for androgenetic alopecia
- Neurological conditions, including neuropathy, traumatic brain injury, and cognitive decline
- Hormonal imbalances such as thyroid disorders, PCOS, low testosterone, and adrenal fatigue
- Dental conditions, including oral mucositis and temporomandibular joint disorders
- Gut health and digestive inflammation
- Seasonal affective disorder (SAD) and mood regulation
- Lymphedema and lymphatic drainage support
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10904682/
- https://www.biospace.com/data-published-in-journal-of-inflammation-research-reveal-significantly-better-outcomes-in-covid-19-pneumonia-patients-treated-with-mls-laser-therapy
- https://pubmed.ncbi.nlm.nih.gov/29978558/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11910241/
- https://pubmed.ncbi.nlm.nih.gov/41017014/
- https://link.springer.com/article/10.1007/s10103-021-03359-1
- https://pubmed.ncbi.nlm.nih.gov/39134306/
- https://pubmed.ncbi.nlm.nih.gov/35185864/
- https://almclinmed.ru/jour/article/xml/233/
- https://www.springermedizin.de/transcutaneous-systemic-photobiomodulation-reduced-lung-inflamma/19275010
- https://pubmed.ncbi.nlm.nih.gov/39199248/
- https://www.almclinmed.ru/jour/article/view/233/0
- https://trial.medpath.com/clinical-trial/ae18f2b6599b82d5/effects-photobiomodulation-immune-system-neonates-infants
- https://www.jkslms.or.kr/journal/popup_file.html?uid=381&file=&md=tbl&idx=4
- https://ichgcp.net/da/clinical-trials-registry/NCT06396624
- https://onlinelibrary.wiley.com/doi/full/10.1155/2018/6270614
- https://koreascience.kr/ksci/search/article/articleView.ksci?articleBean.atclMgntNo=OOSCB@_2019_v40n4_125
- https://pubmed.ncbi.nlm.nih.gov/38358423/
- https://kci.go.kr/kciportal/landing/article.kci?arti_id=ART002497422
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11917203/
- https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART00317532of8
- https://link.springer.com/article/10.1007/s10103-025-04736-w
- https://fotonmedix.com/advanced-photobiomodulation-in-ent-the-clinical-integration-of-class-iv-therapy-lasers-for-chronic-rhinosinusitis-and-neuropathic-facial-pain.html/
- https://pesquisa1.bvsalud.org/mtci/resource/en/mdl-21290392
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9883131/
- https://www.springermedizin.de/de/acute-effects-of-photobiomodulation-therapy-applied-to-respirato/17310576
- https://clinicaltrials.gov/study/NCT03639220
- https://investigadores.anid.cl//en/public_search/work?id=541137
- https://www.socolar.com/Article/Index?aid=100015534453&jid=100000006014
- https://fotonmedix.com/fotonmedix-laser-medical-breakthrough-published-in-a-nature-sub-journalthe-worlds-first-decoding-of-the-laser-therapy-mechanism-for-asthma-and-pneumonia.html/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11276592/
- https://www.jkslms.or.kr/journal/popup_file.html?uid=404&file=&md=tbl&idx=1
- https://www.medscape.com/medline/abstract/34146193
- https://d.wanfangdata.com.cn/periodical/whbb202509016
- https://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_lcyydzzz201873006
- https://www.mayoclinic.org/diseases-conditions/emphysema/symptoms-causes/syc-20355555
- https://www.researchgate.net/publication/349432600_Photobiomodulation_in_the_management_of_acute_respiratory_viral_infections_A_new_treatment_approach
- https://pubmed.ncbi.nlm.nih.gov/26286333/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12830860/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5523874/
- https://www.mdpi.com/2313-5786/5/4/33
- https://read.qxmd.com/read/36495670/cardiopulmonary-and-hematological-effects-of-infrared-led-photobiomodulation-in-the-treatment-of-sars-cov2
- https://ouci.dntb.gov.ua/en/works/4YqpEQ34/
- https://pubmed.ncbi.nlm.nih.gov/34935510/
- https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1710363/xml
- https://www.biospace.com/covid-19-pneumonia-patient-shows-significant-improvements-following-laser-treatment-at-massachusetts-hospital
- https://trial.medpath.com/clinical-trial/9bf2ee45325f9580/nct04391712-mls-laser-therapy-covid-19-pulmonary-disease
- https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1714450/full
- https://read.qxmd.com/read/28712048/photobiomodulation-therapy-improves-both-inflammatory-and-fibrotic-parameters-in-experimental-model-of-lung-fibrosis-in-mice
- https://pulmonaryfibrosisnow.org/2025/08/30/red-light-and-class-iv-laser-therapy/
- https://www.mdpi.com/2075-1729/11/11/1124
- https://pubmed.ncbi.nlm.nih.gov/38940733/
- https://rcseng.ovidds.com/discover/result?logSearchID=161306344&pubid=solr_6057-medline%3A3917187aa6
- https://rcseng.ovidds.com/discover/result?logSearchID=167360107&pubid=solr_7902-info%3Adoi%2F10.1002%252Falr.23532
- https://e-ceo.org/m/journal/view.php?doi=10.21053/ceo.2024.00286
- https://link.springer.com/article/10.1186/s13256-023-03980-4/figures/2
- https://library.cnu.ac.kr/eds/detail/edb_17682175
- https://www.mendeley.com/catalogue/a70cebb8-ed67-3bb7-abe0-94c8a4169bf0/
- https://trial.medpath.com/clinical-trial/75e2a6864667115e/nct03752645-allergic-rhinitis-treatment-groups
- https://link.springer.com/article/10.1007/s10103-018-2645-z?fromPaywallRec=true
- https://link.springer.com/article/10.1007/s43630-025-00784-x
- https://randr19.nist.gov/DocResults?q=acute+dyspnea+and+lung+congestion&db=covidtrend&id=279934
- https://journals_beta.koreamed.org/SearchBasic.php?RID=2565228
- https://fotonmedix.com/zh/advanced-photobiomodulation-in-ent-the-clinical-integration-of-class-iv-therapy-lasers-for-chronic-rhinosinusitis-and-neuropathic-facial-pain.html/
- https://veterans.networkofcare.org/bucks-pa/CommunityResources/ClinicalTrials/Detail/NCT03752645
- https://journals.rcsi.science/1681-3456/article/xml/271594/en_US
- https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003175328
- https://rcseng.ovidds.com/discover/result?logSearchID=161306344&pubid=solr_6057-medline%3A39171876
- https://library.cnu.ac.kr/eds/detail/edb_176826175